Literature DB >> 15923126

Structural characterization of Lipoarabinomannans from Mycobacterium tuberculosis and Mycobacterium smegmatis by ESI mass spectrometry.

Christopher J Petzold1, Leslie H Stanton, Julie A Leary.   

Abstract

Structural aspects of lipoarabinomannans (LAM) from Mycobacterium tuberculosis and Mycobacterium smegmatis were investigated by using mild acid hydrolysis in combination with Fourier-transform ion cyclotron resonance (FT-ICR), and quadrupole ion trap mass spectrometry. Exact mass measurements with less than 2.5 ppm mass error confirmed the presence of a series of arabinose oligomers (Ara(n); n = 2-7) as the major components observed following mild acid hydrolysis of both M. tuberculosis and M. smegmatis LAM. However, the mass spectrum of the resulting LAM extract also revealed a highly-abundant distribution of ions that exact mass measurements identified as mannose-linked arabinose species, Ara(n)Man(m) + Na+ (n = 1-6; m = 1-3). The observed mannose caps were linked to arabinose species as mono-, di-, and trimannose units, and the ratio of the mono-, di-, and trimannose caps was determined to be 1.00:9.00:1.15, respectively, different from previous reports. Analysis of the linkage of lithiated arabinose trimer standards was accomplished with MS3 experiments and the information generated was used to identify linkages of arabinose trimers generated by mild acid hydrolysis of M. tuberculosis and M. smegmatis LAM. The MS3 spectra confirmed the linkage of arabinose trimers from M. smegmatis and M. tuberculosis LAM as predominantly alpha(1 --> 5), alpha(1 --> 5).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15923126     DOI: 10.1016/j.jasms.2005.02.023

Source DB:  PubMed          Journal:  J Am Soc Mass Spectrom        ISSN: 1044-0305            Impact factor:   3.109


  28 in total

Review 1.  Roles of lipoarabinomannan in the pathogenesis of tuberculosis.

Authors:  G R Strohmeier; M J Fenton
Journal:  Microbes Infect       Date:  1999-07       Impact factor: 2.700

Review 2.  Mycobacterial lipoarabinomannan: an extraordinary lipoheteroglycan with profound physiological effects.

Authors:  D Chatterjee; K H Khoo
Journal:  Glycobiology       Date:  1998-02       Impact factor: 4.313

3.  5-Methylthiopentose: a new substituent on lipoarabinomannan in Mycobacterium tuberculosis.

Authors:  Achim Treumann; Feng Xidong; Liam McDonnell; Peter J Derrick; Alison E Ashcroft; Delphi Chatterjee; Steve W Homans
Journal:  J Mol Biol       Date:  2002-02-08       Impact factor: 5.469

4.  Variation in mannose-capped terminal arabinan motifs of lipoarabinomannans from clinical isolates of Mycobacterium tuberculosis and Mycobacterium avium complex.

Authors:  K H Khoo; J B Tang; D Chatterjee
Journal:  J Biol Chem       Date:  2000-11-09       Impact factor: 5.157

5.  Stabilization and linkage analysis of metal-ligated sialic acid containing oligosaccharides.

Authors:  M D Leavell; J A Leary
Journal:  J Am Soc Mass Spectrom       Date:  2001-05       Impact factor: 3.109

6.  CD1-restricted T cell recognition of microbial lipoglycan antigens.

Authors:  P A Sieling; D Chatterjee; S A Porcelli; T I Prigozy; R J Mazzaccaro; T Soriano; B R Bloom; M B Brenner; M Kronenberg; P J Brennan
Journal:  Science       Date:  1995-07-14       Impact factor: 47.728

7.  Inositol phosphate capping of the nonreducing termini of lipoarabinomannan from rapidly growing strains of Mycobacterium.

Authors:  K H Khoo; A Dell; H R Morris; P J Brennan; D Chatterjee
Journal:  J Biol Chem       Date:  1995-05-26       Impact factor: 5.157

8.  Stereochemical differentiation of mannose, glucose, galactose, and talose using zinc(II) diethylenetriamine and ESI-ion trap mass spectrometry.

Authors:  S P Gaucher; J A Leary
Journal:  Anal Chem       Date:  1998-07-15       Impact factor: 6.986

9.  Binding of the terminal mannosyl units of lipoarabinomannan from a virulent strain of Mycobacterium tuberculosis to human macrophages.

Authors:  L S Schlesinger; S R Hull; T M Kaufman
Journal:  J Immunol       Date:  1994-04-15       Impact factor: 5.422

Review 10.  The envelope of mycobacteria.

Authors:  P J Brennan; H Nikaido
Journal:  Annu Rev Biochem       Date:  1995       Impact factor: 23.643

View more
  4 in total

1.  A truncated lipoglycan from mycobacteria with altered immunological properties.

Authors:  Helen L Birch; Luke J Alderwick; Ben J Appelmelk; Janneke Maaskant; Apoorva Bhatt; Albel Singh; Jerome Nigou; Lothar Eggeling; Jeroen Geurtsen; Gurdyal S Besra
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-25       Impact factor: 11.205

2.  Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts.

Authors:  Masanori Kawasaki; Carmenchu Echiverri; Lawrence Raymond; Elizabeth Cadena; Evelyn Reside; Maria Tarcela Gler; Tetsuya Oda; Ryuta Ito; Ryo Higashiyama; Kiyonori Katsuragi; Yongge Liu
Journal:  PLoS Med       Date:  2019-04-12       Impact factor: 11.069

3.  Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis.

Authors:  Jason L Cantera; Lorraine M Lillis; Roger B Peck; Emmanuel Moreau; James A Schouten; Paul Davis; Paul K Drain; Alfred Andama; Abraham Pinter; Masanori Kawasaki; Gunilla Källenius; Christopher Sundling; Karen M Dobos; Danara Flores; Delphi Chatterjee; Eileen Murphy; Olivia R Halas; David S Boyle
Journal:  PLoS One       Date:  2022-09-30       Impact factor: 3.752

4.  Characterization of the Antigenic Heterogeneity of Lipoarabinomannan, the Major Surface Glycolipid of Mycobacterium tuberculosis, and Complexity of Antibody Specificities toward This Antigen.

Authors:  Alok Choudhary; Deendayal Patel; William Honnen; Zhong Lai; Raja Sekhar Prattipati; Ruixiang Blake Zheng; Ying-Chao Hsueh; Maria Laura Gennaro; Alfred Lardizabal; Blanca I Restrepo; Moncerrato Garcia-Viveros; Maju Joe; Yu Bai; Ke Shen; Kamar Sahloul; John S Spencer; Delphi Chatterjee; Tobias Broger; Todd L Lowary; Abraham Pinter
Journal:  J Immunol       Date:  2018-04-02       Impact factor: 5.422

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.